Advances in stent drug delivery: the future is in bioabsorbable stents

Bibliography

• Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet 2007;369(9562):667-78
   PubMed Web of Science ®Google Scholar
• Pfisterer M, Brunner-La Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol 2006;48(12):2584-91
   PubMed Web of Science ®Google Scholar
• Windecker S, Serruys PW, Wandel S, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet 2008;372:1163-72
   PubMed Web of Science ®Google Scholar
• Aoki J, Serruys PW, van Beusekom H, et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. J Am Coll Cardiol 2005;45(10):1574-9
   PubMed Web of Science ®Google Scholar
• Rajtar A KGL, Yang Q, Hakimi D, et al. Hydroxyapatite-coated cardiovascular stents. EuroIntervention 2006;2(5):113-15
   PubMedGoogle Scholar
• Ramcharitar S and Serruys PW. Fully Biodegradable Coronary Stents. Am J Cardiovasc Drugs 2008;8(5):305-14
   PubMed Web of Science ®Google Scholar
• Kukreja N, Onuma Y, Daemen J, Serruys PW. The future of drug-eluting stents. Pharmacol Res 2008;57(3):171-80
   PubMed Web of Science ®Google Scholar
• Mori K, Saito T. Effects of stent structure on stent flexibility measurements. Ann Biomed Eng 2005;33(6):733-42
   PubMed Web of Science ®Google Scholar
• Hwang CW, Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation 2001;104(5):600-5
   PubMed Web of Science ®Google Scholar
• Hwang CW, Wu D, Edelman ER. Impact of transport and drug properties on the local pharmacology of drug-eluting stents. Int J Cardiovasc Intervent 2003;5(1):7-12
   PubMedGoogle Scholar
• Acharya G, Park K. Mechanisms of controlled drug release from drug-eluting stents. Adv Drug Deliv Rev 2006;58(3):387-401
   PubMed Web of Science ®Google Scholar
• Lansky AJ, Costa RA, Mintz GS, et al. Non-polymer-based paclitaxel-coated coronary stents for the treatment of patients with de novo coronary lesions: angiographic follow-up of the DELIVER clinical trial. Circulation 2004;109(16):1948-54
   PubMed Web of Science ®Google Scholar
• Nakayama Y, Nishi S, Ueda-ishibashi H, Matsuda T. Fabrication of micropored elastomeric film-covered stents and acute-phase performances. J Biomed Mater Res A 2003;64(1):52-61
   PubMedGoogle Scholar
• Hiatt BL, Ikeno F, Yeung AC, Carter AJ. Drug-eluting stents for the prevention of restenosis: in quest for the Holy Grail. Catheter Cardiovasc Interv 2002;55(3):409-17
   PubMed Web of Science ®Google Scholar
• Kamath KR, Barry JJ, Miller KM. The Taxus drug-eluting stent: a new paradigm in controlled drug delivery. Adv Drug Deliv Rev 2006;58(3):412-36
   PubMed Web of Science ®Google Scholar
• Rechavia E, Litvack F, Fishbien MC, et al. Biocompatibility of polyurethane-coated stents: tissue and vascular aspects. Catheter Cardiovasc Diagn 1998;45(2):202-7
   PubMedGoogle Scholar
• Holmes DR, Camrud AR, Jorgenson MA, et al. Polymeric stenting in the porcine coronary artery model: differential outcome of exogenous fibrin sleeves versus polyurethane-coated stents. J Am Coll Cardiol 1994;24(2):525-31
   PubMed Web of Science ®Google Scholar
• van der Giessen WJ, Lincoff AM, Schwartz RS, et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996;94(7):1690-7
   PubMed Web of Science ®Google Scholar
• Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet 1978;1(8058):263
   PubMed Web of Science ®Google Scholar
• Turina M, Gruntzig A, Krayenbuhl C, Senning A. The role of the surgeon in percutaneous transluminal dilation of coronary stenosis. Ann Thorac Surg 1979;28(2):103-12
   PubMed Web of Science ®Google Scholar
• Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994;331(8):489-95
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994;331(8):496-501
   PubMed Web of Science ®Google Scholar
• Sigwart U, Puel J, Mirkovitch V, et al. Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med 1987;316(12):701-6
   PubMed Web of Science ®Google Scholar
• Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006;354(5):483-95
   PubMed Web of Science ®Google Scholar
• Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334(17):1084-9
   PubMed Web of Science ®Google Scholar
• Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000;102(6):624-9
   PubMed Web of Science ®Google Scholar
• Costa MA, Sabate M, van der Gissen WT, et al. Late coronary occlusion after intracoronary brachytherapy. Circulation 1999;100(8):789-92
   PubMed Web of Science ®Google Scholar
• Waksman R. Late thrombosis after radiation. Sitting on a time bomb. Circulation 1999;100(8):780-2
   PubMedGoogle Scholar
• Morice MC, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346(23):1773-80
   PubMed Web of Science ®Google Scholar
• Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003;349(14):1315-23
   PubMed Web of Science ®Google Scholar
• Urban P, Gershlick AH, Guagliumi G, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation 2006;113(11):1434-41
   PubMed Web of Science ®Google Scholar
• Lemos PA, Serruys PW, van Domburg RT, et al. Unrestricted utilization of sirolimus-eluting stents compared with conventional bare stent implantation in the ‘real world’: the Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital (RESEARCH) registry. Circulation 2004;109(2):190-5
   PubMed Web of Science ®Google Scholar
• Daemen J, Tanimoto S, Garcia-garcia HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol 2007;99(8):1027-32
   PubMed Web of Science ®Google Scholar
• Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370(9591):937-48
   PubMed Web of Science ®Google Scholar
• Joner M, Finn AV, Farb A, et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol 2006;48(1):193-202
   PubMed Web of Science ®Google Scholar
• Takano M, Yamamoto M, Xie Y, et al. Serial long-term evaluation of neointimal stent coverage and thrombus after sirolimus-eluting stent implantation by use of coronary angioscopy. Heart (British Cardiac Society) 2007;93(12):1533-6
   PubMed Web of Science ®Google Scholar
• Colombo A, Drzewiecki J, Banning A, et al. Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions. Circulation 2003;108(7):788-94
   PubMed Web of Science ®Google Scholar
• Ong AT, Serruys PW, Aoki J, et al. The unrestricted use of paclitaxel- versus sirolimus-eluting stents for coronary artery disease in an unselected population: one-year results of the Taxus-Stent Evaluated at Rotterdam Cardiology Hospital (T-SEARCH) registry. J Am Coll Cardiol 2005;45(7):1135-41
   PubMed Web of Science ®Google Scholar
• Kandzari DE, Leon MB, Popma JJ, et al. Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial. J Am Coll Cardiol 2006;48(12):2440-7
   PubMed Web of Science ®Google Scholar
• Fajadet J, Wijns W, Laarman GJ, et al. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006;114(8):798-806
   PubMed Web of Science ®Google Scholar
• Sakurai R, Bonneau HN, Honda Y, Fitzgerald PJ. Intravascular ultrasound findings in ENDEAVOR II and ENDEAVOR III. Am J Cardiol 2007;100(8B):71M-76M
   PubMed Web of Science ®Google Scholar
• Sakurai R, Hongo Y, Yamasaki M, et al. Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial). Am J Cardiol 2007;100(5):818-23
   PubMed Web of Science ®Google Scholar
• Onuma YMR, Ramcharitar S, Geuns RJ, et al. Tryton I, First-In-Man (FIM) study: sox month clinical and angiographic outcome, analysis with new quantitative coronary angiography dedicated for bifurcation lesions. EuroIntervention 2008;3(5):546-52
   PubMedGoogle Scholar
• Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008;299(16):1903-13
   PubMed Web of Science ®Google Scholar
• Serruys PW, Ruygrook P, Neuzner J, et al. A randomized comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. EuroIntervention 2006;2:286-94
   PubMedGoogle Scholar
• Finn AV, Joner M, Nakazawa G, et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 2007;115(18):2435-41
   PubMed Web of Science ®Google Scholar
• Finn AV, Nakazawa G, Joner M, et al. Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol 2007;27(7):1500-10
   PubMed Web of Science ®Google Scholar
• Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007;356(10):1020-9
   PubMed Web of Science ®Google Scholar
• Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol 2008;52(5):333-42
   PubMed Web of Science ®Google Scholar
• Ormiston JA, Serruys PW, Regar E, et al. A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet 2008;371(9616):899-907
   PubMed Web of Science ®Google Scholar
• Tanimoto S, Serruys PW, Thuesen L, et al. Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials. Catheter Cardiovasc Interv 2007;70(4):515-23
   PubMed Web of Science ®Google Scholar
• Stella PR, Mueller R, Pavlakis G, et al. One year results of a new in situ length-adjustable stent platform with a biodegradable Biolimus A9 eluting polymer: results of the CUSTOM-II trial. EuroIntervention 2008;4(2):200-7
   PubMedGoogle Scholar
• Windecker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001;104(8):928-33
   PubMed Web of Science ®Google Scholar
• Windecker S, Simon R, Lins M, et al. Randomized comparison of a titanium-nitride-oxide-coated stent with a stainless steel stent for coronary revascularization: the TiNOX trial. Circulation 2005;111(20):2617-22
   PubMed Web of Science ®Google Scholar
• Kaplan AV, RS, Louvard Y, Muller R, et al. Tryton I, First-In-Man (FIM) Study: acute and 30 day outcome. A preliminary report. EuroIntervention 2007;3(1):54-9
   PubMedGoogle Scholar
• Han Y, Jing Q, Chen X, et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 2008;72(2):177-83
   PubMed Web of Science ®Google Scholar
• Krucoff MW, Kereiakes DJ, Petersen JL, et al. A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study. J Am Coll Cardiol 2008;51(16):1543-52
   PubMed Web of Science ®Google Scholar
• Morice MC, BHP, Carrie D, Macaya C, et al. Direct stenting of de novo coronary stenoses with tacrolimus-eluting versus-coated carbostents. The randomized JUPITER II trial. EuroIntervention 2006;2:45-52
   PubMedGoogle Scholar
• Tanimoto S, van der Gissen W, van Beusekom HM, et al. Mahoroba: tacrolimus eluting coronary stent. EuroIntervention 2007;3:149-53
   PubMedGoogle Scholar
• Duckers HJ, ST, den Heijer P, Rensing B, de Winter RJ, et al. Accelerated vascular repair following percutaneous coronary intervention by capture of endothelial progenitor cells promotes regression of neointimal growth at long term follow-up: final result of the Healing II trial using an endothelial progenitor cell capturing stent (Genous R stent). EuroIntervention 2007;3:350-8
   PubMedGoogle Scholar
• Stefanadis C, Toutouzas K, Stefanadi E, et al. Avastin-eluting stent: long-term angiographic and clinical follow up. Hellenic J Cardiol 2008;49(3):188-90
   PubMed Web of Science ®Google Scholar
• Stefanadis C, Toutouzas K, Stefanadi E, et al. Inhibition of plaque neovascularization and intimal hyperplasia by specific targeting vascular endothelial growth factor with bevacizumab-eluting stent: an experimental study. Atherosclerosis 2007;195(2):269-76
   PubMed Web of Science ®Google Scholar
• Erbel R, Bose D, Haude M, et al. [Absorbable coronary stents. New promising technology]. Herz 2007;32(4):308-19
   PubMed Web of Science ®Google Scholar
• Erbel R, Di Mario, C Bartunek, et al. Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet 2007;369(9576):1869-75
   PubMed Web of Science ®Google Scholar
• Tamai H, Igaki K, Kyo E, et al. Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation 2000;102(4):399-404
   PubMed Web of Science ®Google Scholar
• Ramcharitar S, Serruys PW. Fully biodegradable coronary stents: progress to date. Am J Cardiovasc Drugs 2008;8(5):305-14
   PubMed Web of Science ®Google Scholar